Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
European Journal of Cancer (Oxford, England : 1990)|August 10, 2015
Concurrent Etoposide, Steroid, High-dose Ara-C and Platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal typeJean-Marie Michot, Renaud Mazeron, Alina Danu, et al.
Blood|March 9, 2017
Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphomaCharles Herbaux, Jordan Gauthier, Pauline Brice, et al.
Blood Advances|April 12, 2021
The landscape of copy number variations in classical Hodgkin lymphoma: a joint KU Leuven and LYSA study on cell-free DNALieselot Buedts, Iwona Wlodarska, Julio Finalet-Ferreiro, et al.
Cancer Medicine|February 24, 2018
Central nervous system relapse in patients over 80 years with diffuse large B-cell lymphoma: an analysis of two LYSA studiesAurélie Cabannes-Hamy, Frederic Peyrade, Fabrice Jardin, et al.
Bulletin Du Cancer|January 1, 2018
[Hodgkin lymphoma: Current and future therapeutic strategies]Anthony Turpin, Jean-Marie Michot, Emmanuelle Kempf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2021
Gonadal Function Recovery in Patients With Advanced Hodgkin Lymphoma Treated With a PET-Adapted Regimen: Prospective Analysis of a Randomized Phase III Trial (AHL2011)Isabelle Demeestere, Judith Racape, Julie Dechene, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2023
Long-Term Follow-Up of the Response-Adapted Intergroup EORTC/LYSA/FIL H10 Trial for Localized Hodgkin LymphomaMassimo Federico, Catherine Fortpied, Yana Stepanishyna, et al.
Investigational New Drugs|June 10, 2017
Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trialsJean-Marie Michot, Lina Benajiba, Laura Faivre, et al.
Pageof 5